Retina

ARCATUS or ARVN001 was developed by Clearside Biomedical and commercialised in the Asia-Pacific region by Arctic Vision

Predictive software will use retinal imaging to identify patient risk for Alzheimer and other neurodegenerative diseases

The study findings suggest that patients should be educated about adherence to cold storage guidelines

The updated device is designed to meet market diagnostic needs, including within geographic atrophy research

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

The commercialisation agreements for the biosimilar to aflibercept (Eylea) cover Israel, major parts of Europe and the Asia-Pacific Region

The study built on previous research indicating specific retinal variables can serve as disease-related biomarkers in neurodegenerative diseases

The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular oedema

Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer

The RESTORE Study is the follow-up study of the RESCUE and REVERSE studies of lenadogene nolparvovec to treat vision loss from LHON

Investigators emphasised the need for continued efforts to raise awareness and support patients in attending regular screening

Hot topics around the globe, from clinical trials to the solar eclipse

Highlights from the year, courtesy of our colleagues at Ophthalmology Times

Trending topics and milestone stories from our year in ophthalmology

The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes

Our top 10 print stories highlight the core content concepts we explored this year

Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology

The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)

The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion

A retrospective study assessed elevated neutrophil-to-lymphocyte ratios and systemic immune-inflammation index levels in patients with different subtypes of DMO

Clinicians must consider redefining the metrics and intention behind functional outcomes, according to experts from the European Association for the Study of Diabetic Eye Complications

Presentation closely resembled mitogen-activated extracellular signal-regulated kinase inhibitor–associated retinopathy